Edition:
United States

Cocrystal Pharma Inc (COCP.OQ)

COCP.OQ on NASDAQ Stock Exchange Capital Market

4.14USD
17 Aug 2018
Change (% chg)

$0.39 (+10.40%)
Prev Close
$3.75
Open
$3.74
Day's High
$4.14
Day's Low
$3.74
Volume
836
Avg. Vol
23,398
52-wk High
$6.43
52-wk Low
$1.61

Chart for

About

Cocrystal Pharma, Inc., is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $132.25
Shares Outstanding(Mil.): 31.94
Dividend: --
Yield (%): --

Financials

  COCP.OQ Industry Sector
P/E (TTM): 588.07 28.29 30.45
EPS (TTM): 0.01 -- --
ROI: 0.03 12.92 12.63
ROE: 0.04 14.94 14.82

BRIEF-Cocrystal Pharma Posts Qtrly Net Loss Of About $1.6 Mln

* COCRYSTAL PHARMA REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 11 2018

BRIEF-Cocrystal Pharma Prices $8,000,000 Common Stock Offering

* COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING

May 01 2018

BRIEF-Cocrystal Pharma Receives FDA Clearance To Initiate Phase 2A Clinical Study Evaluating CC 31244 For Treatment Of Hepatitis C Virus

* 31244 WITH APPROVED HCV DRUGS Source text for Eikon: Further company coverage:

Apr 03 2018

BRIEF-Cocrystal Pharma Provides Corporate Overview

* COCRYSTAL PHARMA REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE OVERVIEW AND BUSINESS OUTLOOK

Mar 22 2018

BRIEF-Cocrystal Pharma Files For Non Timely 10-K

* COCRYSTAL PHARMA INC FILES FOR NON TIMELY 10-K - SEC FILING‍​ Source text - http://bit.ly/2FMME8d Further company coverage:

Mar 19 2018

Earnings vs. Estimates